A clinical drug development programme to evaluate and compare the safety and efficacy of new regimens of Lifecare's Liposomal Amphotericin b (FUNGISOMETM) against currently accepted therapies for the treatment of Kala Azar; A Phase III, Open Label Randomized Trial of Three Single Dose Treatment regimens of FUNGISOMETM ALONE OR IN Combination with Miltefosine compared with single Dose Treatment regimen of AmBisome for visceral Leishmaniasis in India
Lifecare Innovations Private Limited, Gurgaon, Haryana (122018)
Accessibility Controls